All studies
AuthorisedHuman Pharmacology (Phase I)- OtherInterventional

An open-label, DDI study to investigate the effects of duvakitug on the PK of selected cytochrome P450 substrates

This clinical trial is studying an experimental medicine called duvakitug. It is being developed as a potential treatment for inflammatory bowel conditions, including ulcerative colitis and Crohn’s disease. When people take medicines, the liver uses natural proteins called enzymes to break them down and clear them from the body. Sometimes, one medicine can speed up or slow down how another medicine is handled. This is called a drug-drug interaction. In this study, researchers want to see whether duvakitug affects liver enzymes known as cytochrome P450. Participants will receive duvakitug along with small test doses of other standard medicines. Researchers will take blood samples to measure how quickly these medicines pass through the body. This is an 'open-label' study, meaning both you and the study team will know which medicines you receive. The results will help doctors safely prescribe duvakitug in the future.

At a glance

Status
Authorised
Phase
Human Pharmacology (Phase I)- Other
Sponsor
Sanofi-Aventis Recherche & Developpement
Enrolment target
50
Start
30 Sep 2026

What is this study about?

Crohn’s disease and ulcerative colitis are long-term conditions that cause painful swelling and irritation in the digestive system. Scientists are working hard to find new, more targeted treatments to help calm this inflammation. Duvakitug is a new experimental drug designed to help treat these conditions, but before it can be widely used, doctors must know how safe it is.

Many people living with inflammatory bowel diseases need to take several different medications at the same time. The body breaks down most medicines in the liver using special tools called enzymes. One important group of these tools is called cytochrome P450. If a new medicine blocks or speeds up these enzymes, it can cause other medicines in your body to build up to unsafe levels or get washed away too quickly to work.

This trial is a 'drug interaction' study. Its main purpose is not yet to cure gut symptoms, but to closely track how duvakitug and common liver enzymes interact. By measuring levels of medicines in the blood over time, researchers can see if duvakitug alters how the body processes other treatments.

Understanding these interactions is a vital safety step. The findings will guide future research and give doctors the clear instructions they need to prescribe duvakitug safely alongside other routine treatments.

Key takeaways

  • The trial tests how an experimental drug, duvakitug, interacts with other medicines.
  • It aims to support new treatments for ulcerative colitis and Crohn's disease.
  • This is an open-label study, meaning no dummy treatments (placebos) are used.
  • Participants must be adults aged 18 or older.
  • Taking part involves clinic visits, taking study medicines, and regular blood tests.

Who may be eligible?

This trial is open to adults aged 18 and older. Because this is an early-stage pharmacology study focused on how medicines move through the body, the researchers have specific safety rules about who can take part.

Generally, you must be in good overall health or have stable bowel disease, and your liver and kidneys must be working well so the results can be measured accurately. Men and women of any background can join, provided they meet the basic study criteria.

People who take certain regular medications, herbal supplements, or who have specific medical conditions that might interfere with liver enzymes may not be able to join. The study team will review your full medical history and current prescriptions to make sure it is safe for you to take part.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 18 or older.
  2. I have been diagnosed with Crohn's disease, ulcerative colitis, or meet the trial's health requirements.
  3. I am willing to attend regular clinic appointments and have frequent blood tests.
  4. I can temporarily pause or avoid certain medications or supplements if advised by the study team.
  5. My liver and kidneys are generally in good working order.
Answer every question to see your result.

What does participation involve?

Taking part in this study involves several stages over a set period of weeks. First, you will attend a screening visit where doctors will check your general health, take blood and urine samples, and review your medical history to confirm the study is safe for you.

If you join, you will be given duvakitug along with small, safe test doses of standard medicines that are broken down by liver enzymes. Because this is an open-label trial, there is no dummy drug (placebo); you and the medical team will know exactly what you are taking.

You will need to visit the clinic regularly, and you may be asked to stay at the research unit for short periods. During these visits, nurses will take blood samples at set times to measure drug levels in your bloodstream. You will also have your heart rate, blood pressure, and overall wellbeing monitored closely. After the treatment phase ends, there will be a follow-up visit to check on your health.

Potential risks and benefits

Taking part in this trial may not directly improve your bowel condition, as its primary goal is to study how drugs interact in the body. However, your participation will provide vital information that could help bring a safe, new treatment to people living with Crohn’s or colitis in the future. As with any new medicine, there are risks of unwanted side effects, which the medical team will explain in detail. You may also experience minor discomfort or bruising from frequent blood tests. Your safety is monitored throughout, and you are entirely free to leave the study at any time without giving a reason and without affecting your normal NHS care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    Germany

Common questions

What does 'open-label' mean?

It means that both you and the research doctors know which medicines you are receiving. There are no dummy pills or placebos used in this part of the study.

Why is this study looking at liver enzymes?

Your liver uses enzymes to break down everyday medicines. Testing duvakitug with these enzymes shows doctors if it will change how your other medicines work.

Will taking part cure my Crohn's or colitis?

No. This is an early-stage study designed to check medicine safety and interactions, not to cure your condition.

Do I have to pay to take part?

No, clinical trials in the UK do not charge participants. Travel expenses and time commitments are often reimbursed by the study sponsor.

Can I leave the study if I change my mind?

Yes. Taking part is completely voluntary, and you can stop at any point without your standard medical care being affected.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.